Nonprofits›Oxfendazole Development Group
Medical Research
Oxfendazole Development Group
BLUE BELL, PA
Total revenue
$23K
Total expenses
$852K
Net assets
$318K
Grants received
$1.8M
3 grants
EIN
811547477
Tax year
2024
Mission
Research and development of pharmaceutical treatments to help eliminate neglected tropical diseases especially oxfendazole through nonclinical work and the conduct of clinical studies
Financials
FY 2024
Revenue
Contributions & grants$869
Program service revenue—
Investment income$22K
Other revenue—
Total revenue$23K
Expenses
Grants paid—
Salaries & benefits—
Fundraising—
Other expenses$852K
Total expenses$852K
Total assets$318K
Net assets$318K
People
5 listed
NameRoleCompensation
R John Horton
President Board Member
Board
—
5 hrs/wk
Ellen Codd
Treasurer Board Member
Board
—
20 hrs/wk
Robert H Gilman
Board Member
Board
—
1 hrs/wk
Timothy Geary
Secretary Board member
Board
—
4 hrs/wk
Javier Bustos
Board member
Board
—
3 hrs/wk
Grants received
Showing 3 of 3
FromAmountPurposeYear
$101K
DEVELOP THE DEWORMING MEDICINE FOR USE AGAINST HUMAN DWELLING PARASITIC WORMS
2021
Funded by
$1.8M from 3 funders · 3 grants · 2017–2022
Silicon Valley Community Foundation
$1.6M · 1 grant · 2022
Johns Hopkins University
$103K · 1 grant · 2017
Effective Ventures Foundation Usa Inc
$101K · 1 grant · 2021
Details
EIN811547477
NTEE codeH80
Subsection03
Ruling date2016-07
Formed2016
Employees0
Volunteers5